Published 14:31 IST, September 28th 2020

COVID-19 study shows nasal spay reduced viral replication in animals

A study conducted by an Aus firm revealed that its novel nasal treatment has proved remarkably successful in reducing COVID-19 viral replication in animals.

Reported by: Vishal Tiwari
Follow: Google News Icon
  • share
null | Image: self
Advertisement

A study conducted by an Australian biotech firm Ena Respiratory revealed that its vel nasal treatment has proved remarkably successful in reducing COVID-19 viral replication in animals. nasal treatment was developed by company to boost natural human immune system to fight common colds and flu. study was led by Public Health England’s (PHE) Deputy Director, Professor Miles Carroll, and was published today on research site, bioRxiv.

Read: Facemasks Can Give People Immunity & Reduce Severity Of COVID-19 Infection: Study

Advertisement

study revealed that vel product, INNA-051, being developed by Ena Respiratory, reduced viral replication by up to 96 percent in animals. INNA-051 compound works by stimulating innate immune system, first line of defence against invasion of pathogens into body. study said that by boosting immune response in this way with INNA-051 prior to infection, ability of COVID-19 virus to infect animals and replicate was dramatically reduced. 

Read: Study: Household Fabrics Masks Effective Against Coronavirus Transmission

Advertisement

Nasal spray proves effective 

"We’ve been amazed by just how effective our treatment has been. By boosting natural immune response of ferrets with our treatment, we’ve seen a rapid eradication of virus. If humans respond in a similar way, benefits of treatment are two-fold. Individuals exposed to virus would most likely rapidly eliminate it, with treatment ensuring that disease does t progress beyond mild symptoms," said Ena Respiratory Managing Director, Dr. Christophe Demaison in a statement on Monday.

Read: Immune System's T Cells Play Bigger Role In Reducing COVID-19 Severity: Study

Ena Respiratory has raised AU$11.7 million from Australian investors and if it gets regulatory approval, company could be ready to test product on humans in less than four months. company said that it is urgently seeking additional funding to accelerate nasal spray’s clinical development and global distribution.

Advertisement

Read: COVID-19 Most Likely To Kill Children From Mirity Groups: US CDC Study
 

14:32 IST, September 28th 2020